Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials.
Novo Nordisk Inc. was sued Friday by five former employees who say the pharmaceutical company mismanages its $2.3 billion ...
The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly ...
As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages ...
A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, ...
Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...
Sun Pharma of India and Mylan Pharmaceuticals of West Virginia seek FDA approval of generic versions of the popular ...
Novo Nordisk's growth slowed and valuation is high, making it not a buy at current prices despite its strong diabetes and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback